Publications by authors named "Steven H Bernstein"

Claim this Profile
C
Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer.
Nataly Manjarrez-Orduño, Laurence C Menard, Selena Kansal, Paul Fischer, Bijal Kakrecha, Steven H Bernstein

Front Immunol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma.
Kevin R Kelly, Jonathan W Friedberg, Steven I Park, Kevin McDonagh, John Hayslip, Steven H Bernstein

Clin Cancer Res· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Fast Real-time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) program: innovative, high-throughput clinical screening of immunotherapies.
Katy L Simonsen, Paula M Fracasso, Steven H Bernstein, Megan Wind-Rotolo, Manish Gupta

Eur J Cancer· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Follicular Lymphoma Tregs Have a Distinct Transcription Profile Impacting Their Migration and Retention in the Malignant Lymph Node.
Hristina Nedelkovska, Alexander F Rosenberg, Shannon P Hilchey, Ollivier Hyrien, W Richard Burack, Steven H Bernstein

PLoS One· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-derived xenografts of low-grade B-cell lymphomas demonstrate roles of the tumor microenvironment.
W Richard Burack, Janice M Spence, John P Spence, Stephen A Spence, Philip J Rock, Steven H Bernstein

Blood Adv· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106.
Robert W Chen, Hongli Li, Steven H Bernstein, Samir Kahwash, Lisa M Rimsza

Br J Haematol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520.
Soham D Puvvada, Hongli Li, Lisa M Rimsza, Steven H Bernstein, Richard I Fisher

Leuk Lymphoma· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased numbers of CD23(+) CD21(hi) Bin-like B cells in human reactive and rheumatoid arthritis lymph nodes.
Igor I Kuzin, Stephen L Kates, Yawen Ju, Longze Zhang, Homaira Rahimi, Steven H Bernstein

Eur J Immunol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601.
Brian G Till, Hongli Li, Steven H Bernstein, Richard I Fisher, W Richard Burack

Br J Haematol· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mesenchymal stromal cells support the viability and differentiation of follicular lymphoma-infiltrating follicular helper T-cells.
Michael T Brady, Shannon P Hilchey, Ollivier Hyrien, Stephen A Spence, Steven H Bernstein

PLoS One· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: a novel synergistic therapeutic approach.
Michelle Kiebala, Jolanta Skalska, Carla Casulo, Paul S Brookes, Derick R Peterson, Steven H Bernstein

Exp Hematol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent advances in mantle cell lymphoma: report of the 2013 Mantle Cell Lymphoma Consortium Workshop.
Leo I Gordon, Steven H Bernstein, Pedro Jares, Brad S Kahl, Thomas E Witzig

Leuk Lymphoma· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma.
Paul M Barr, Thomas P Miller, Jonathan W Friedberg, Derick R Peterson, Andrea M Baran, Steven H Bernstein

Blood· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.
Jonathan W Friedberg, Daruka Mahadevan, Erin Cebula, Daniel Persky, Izidore Lossos, Steven H Bernstein

J Clin Oncol· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Herpes zoster complicating bortezomib therapy of relapsed/refractory indolent B-cell and mantle cell lymphoma: an analysis of two phase II trials.
Melhem Solh, Richard I Fisher, André Goy, Sven de Vos, Steven H Bernstein

Leuk Lymphoma· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent advances in mantle cell lymphoma: report of the 2012 Mantle Cell Lymphoma Consortium Workshop.
Michael E Williams, Steven H Bernstein, Pedro Jares, Brad S Kahl, Thomas E Witzig

Leuk Lymphoma· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biological functions of ecto-enzymes in regulating extracellular adenosine levels in neoplastic and inflammatory disease states.
Maria Serena Longhi, Simon C Robson, Steven H Bernstein, Sara Serra, Silvia Deaglio

J Mol Med (Berl)· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era.
Makiko Ban-Hoefen, Jennifer L Kelly, Steven H Bernstein, Jane Liesveld, Louis Constine

Leuk Lymphoma· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Late relapses following high-dose autologous stem cell transplantation (HD-ASCT) for Hodgkin's lymphoma (HL) in the ABVD therapeutic era.
Sarah F Keller, Jennifer L Kelly, Elizabeth Sensenig, Jennifer Andreozzi, Jamie Oliva, Steven H Bernstein

Biol Blood Marrow Transplant· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The mitochondrial ATP-dependent Lon protease: a novel target in lymphoma death mediated by the synthetic triterpenoid CDDO and its derivatives.
Steven H Bernstein, Sundararajan Venkatesh, Min Li, Jae Lee, Bin Lu

Blood· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma.
Stephanie J Carter, Steven H Bernstein, Jonathan W Friedberg, Paul M Barr

Leuk Res· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Follicular lymphoma tumor-infiltrating T-helper (T(H)) cells have the same polyfunctional potential as normal nodal T(H) cells despite skewed differentiation.
Shannon P Hilchey, Alexander F Rosenberg, Ollivier Hyrien, Shelley Secor-Socha, Matthew R Cochran, Steven H Bernstein

Blood· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intra-arterial methylprednisolone for the management of steroid-refractory acute gastrointestinal and hepatic graft versus host disease.
Laurie A Milner, Michael W Becker, Steven H Bernstein, Lauren Bruckner, Jonathan W Friedberg

Am J Hematol· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I trial: dose escalation of melphalan in the "BEAM" regimen using amifostine cytoprotection.
Gordon L Phillips, Steven H Bernstein, Jane L Liesveld, Camille N Abboud, Michael W Becker

Biol Blood Marrow Transplant· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma.
Jonathan W Friedberg, Julie M Vose, Jennifer L Kelly, Faith Young, Steven H Bernstein

Blood· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis